According to the 2019NCCN guidelines, immunocheckpoint inhibitors are recommended for
first-line treatment of metastatic colon cancer patients with high microsatellite instability
(msi-h) or mismatched gene deletion (dMMR) who are not suitable for intensive treatment, and
for all patients with second-line or above msi-h /dMMR treatment.This study is a
single-center, single-arm phase II study of the use of triplezumab (JS001) combined with
CAPEOX regimen in the neoadjuvant therapy of msi-h /dMMR for locally advanced colon cancer.
The subjects received neoadjuvant therapy with triplezumab (JS001) combined with CAPEOX
regimen, with one treatment cycle every 3 weeks and two cycles of surgery followed by
Locally Advanced Colon Cancer
Clinical Study Identifier
The First Affiliated Hospital of Xiamen University
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.